(CLB) Core Laboratories - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: NL0000200384
Stock: Reservoir, Analysis, Enhancement, Diagnostics
Total Rating 59
Risk 87
Buy Signal -0.23
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 0.29% |
| Yield on Cost 5y | 0.11% |
| Yield CAGR 5y | 0.00% |
| Payout Consistency | 87.5% |
| Payout Ratio | 5.3% |
| Risk 5d forecast | |
|---|---|
| Volatility | 47.5% |
| Relative Tail Risk | -6.86% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.41 |
| Alpha | -18.00 |
| Character TTM | |
|---|---|
| Beta | 1.581 |
| Beta Downside | 1.647 |
| Drawdowns 3y | |
|---|---|
| Max DD | 64.29% |
| CAGR/Max DD | -0.16 |
Description: CLB Core Laboratories December 26, 2025
Core Laboratories Inc. (CLB) delivers reservoir description and production-enhancement services to oil- and-gas operators worldwide. Its Reservoir Description segment characterizes rock and fluid samples, supports carbon-capture, geothermal and mining projects, and provides laboratory-based analyses of crude and refined products. The Production Enhancement segment focuses on well-completion diagnostics, perforations, stimulations, and solutions to improve enhanced-oil-recovery (EOR) performance, including well-abandonment services.
Key recent metrics: CLB reported FY 2024 revenue of approximately $1.1 billion, with an adjusted EBITDA margin near 22%, reflecting strong demand for EOR diagnostics amid rising oil prices. The company’s exposure to oil-price cycles is a primary economic driver, while the broader Oil & Gas Equipment & Services sector is increasingly influenced by ESG-related investments in carbon-capture and geothermal projects, which are expanding CLB’s service addressable market.
For a deeper dive into CLB’s valuation and risk profile, consider exploring ValueRay’s analyst toolkit for additional data and scenario analysis.
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income: 31.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA -3.50 > 1.0 |
| NWC/Revenue: 21.88% < 20% (prev 24.63%; Δ -2.75% < -1%) |
| CFO/TA 0.06 > 3% & CFO 37.8m > Net Income 31.8m |
| Net Debt (183.5m) to EBITDA (76.2m): 2.41 < 3 |
| Current Ratio: 2.07 > 1.5 & < 3 |
| Outstanding Shares: last quarter (46.5m) vs 12m ago -2.66% < -2% |
| Gross Margin: 17.65% > 18% (prev 0.17%; Δ 1748 % > 0.5%) |
| Asset Turnover: 88.70% > 50% (prev 88.73%; Δ -0.03% > 0%) |
| Interest Coverage Ratio: 5.71 > 6 (EBITDA TTM 76.2m / Interest Expense TTM 9.86m) |
Altman Z'' 3.78
| A: 0.19 (Total Current Assets 222.4m - Total Current Liabilities 107.2m) / Total Assets 597.0m |
| B: 0.29 (Retained Earnings 173.6m / Total Assets 597.0m) |
| C: 0.09 (EBIT TTM 56.4m / Avg Total Assets 593.7m) |
| D: 0.88 (Book Value of Equity 279.8m / Total Liabilities 317.2m) |
| Altman-Z'' Score: 3.78 = AA |
Beneish M -3.17
| DSRI: 0.89 (Receivables 113.5m/127.4m, Revenue 526.6m/523.8m) |
| GMI: 0.96 (GM 17.65% / 16.87%) |
| AQI: 0.98 (AQ_t 0.35 / AQ_t-1 0.36) |
| SGI: 1.01 (Revenue 526.6m / 523.8m) |
| TATA: -0.01 (NI 31.8m - CFO 37.8m) / TA 597.0m) |
| Beneish M-Score: -3.17 (Cap -4..+1) = AA |
What is the price of CLB shares?
As of February 07, 2026, the stock is trading at USD 18.56 with a total of 502,897 shares traded.
Over the past week, the price has changed by -5.02%, over one month by +2.20%, over three months by +21.39% and over the past year by +11.47%.
Over the past week, the price has changed by -5.02%, over one month by +2.20%, over three months by +21.39% and over the past year by +11.47%.
Is CLB a buy, sell or hold?
Core Laboratories has received a consensus analysts rating of 3.00.
Therefor, it is recommend to hold CLB.
- StrongBuy: 0
- Buy: 1
- Hold: 3
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the CLB price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 15.8 | -14.7% |
| Analysts Target Price | 15.8 | -14.7% |
| ValueRay Target Price | 19.2 | 3.2% |
CLB Fundamental Data Overview February 07, 2026
P/E Trailing = 27.6176
P/E Forward = 19.7628
P/S = 1.7018
P/B = 3.3651
P/EG = 1.6717
Revenue TTM = 526.6m USD
EBIT TTM = 56.4m USD
EBITDA TTM = 76.2m USD
Long Term Debt = 114.1m USD (from longTermDebt, two quarters ago)
Short Term Debt = 11.5m USD (from shortTermDebt, last quarter)
Debt = 206.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 183.5m USD (from netDebt column, last quarter)
Enterprise Value = 1.06b USD (880.7m + Debt 206.3m - CCE 22.8m)
Interest Coverage Ratio = 5.71 (Ebit TTM 56.4m / Interest Expense TTM 9.86m)
EV/FCF = 46.37x (Enterprise Value 1.06b / FCF TTM 22.9m)
FCF Yield = 2.16% (FCF TTM 22.9m / Enterprise Value 1.06b)
FCF Margin = 4.36% (FCF TTM 22.9m / Revenue TTM 526.6m)
Net Margin = 6.04% (Net Income TTM 31.8m / Revenue TTM 526.6m)
Gross Margin = 17.65% ((Revenue TTM 526.6m - Cost of Revenue TTM 433.7m) / Revenue TTM)
Gross Margin QoQ = 17.14% (prev 19.35%)
Tobins Q-Ratio = 1.78 (Enterprise Value 1.06b / Total Assets 597.0m)
Interest Expense / Debt = 0.92% (Interest Expense 1.90m / Debt 206.3m)
Taxrate = 45.07% (5.96m / 13.2m)
NOPAT = 31.0m (EBIT 56.4m * (1 - 45.07%))
Current Ratio = 2.07 (Total Current Assets 222.4m / Total Current Liabilities 107.2m)
Debt / Equity = 0.74 (Debt 206.3m / totalStockholderEquity, last quarter 279.8m)
Debt / EBITDA = 2.41 (Net Debt 183.5m / EBITDA 76.2m)
Debt / FCF = 8.00 (Net Debt 183.5m / FCF TTM 22.9m)
Total Stockholder Equity = 266.4m (last 4 quarters mean from totalStockholderEquity)
RoA = 5.36% (Net Income 31.8m / Total Assets 597.0m)
RoE = 11.94% (Net Income TTM 31.8m / Total Stockholder Equity 266.4m)
RoCE = 14.81% (EBIT 56.4m / Capital Employed (Equity 266.4m + L.T.Debt 114.1m))
RoIC = 8.08% (NOPAT 31.0m / Invested Capital 383.0m)
WACC = 9.61% (E(880.7m)/V(1.09b) * Re(11.74%) + D(206.3m)/V(1.09b) * Rd(0.92%) * (1-Tc(0.45)))
Discount Rate = 11.74% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -1.12%
[DCF Debug] Terminal Value 76.22% ; FCFF base≈31.1m ; Y1≈38.4m ; Y5≈65.4m
Fair Price DCF = 13.92 (EV 831.6m - Net Debt 183.5m = Equity 648.1m / Shares 46.6m; r=9.61% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 53.14 | EPS CAGR: 29.35% | SUE: 1.33 | # QB: 2
Revenue Correlation: 74.94 | Revenue CAGR: 4.97% | SUE: 2.79 | # QB: 2
EPS next Quarter (2026-03-31): EPS=0.15 | Chg30d=+0.000 | Revisions Net=-1 | Analysts=2
EPS current Year (2026-12-31): EPS=0.75 | Chg30d=+0.000 | Revisions Net=-2 | Growth EPS=-0.4% | Growth Revenue=-2.2%
P/E Forward = 19.7628
P/S = 1.7018
P/B = 3.3651
P/EG = 1.6717
Revenue TTM = 526.6m USD
EBIT TTM = 56.4m USD
EBITDA TTM = 76.2m USD
Long Term Debt = 114.1m USD (from longTermDebt, two quarters ago)
Short Term Debt = 11.5m USD (from shortTermDebt, last quarter)
Debt = 206.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 183.5m USD (from netDebt column, last quarter)
Enterprise Value = 1.06b USD (880.7m + Debt 206.3m - CCE 22.8m)
Interest Coverage Ratio = 5.71 (Ebit TTM 56.4m / Interest Expense TTM 9.86m)
EV/FCF = 46.37x (Enterprise Value 1.06b / FCF TTM 22.9m)
FCF Yield = 2.16% (FCF TTM 22.9m / Enterprise Value 1.06b)
FCF Margin = 4.36% (FCF TTM 22.9m / Revenue TTM 526.6m)
Net Margin = 6.04% (Net Income TTM 31.8m / Revenue TTM 526.6m)
Gross Margin = 17.65% ((Revenue TTM 526.6m - Cost of Revenue TTM 433.7m) / Revenue TTM)
Gross Margin QoQ = 17.14% (prev 19.35%)
Tobins Q-Ratio = 1.78 (Enterprise Value 1.06b / Total Assets 597.0m)
Interest Expense / Debt = 0.92% (Interest Expense 1.90m / Debt 206.3m)
Taxrate = 45.07% (5.96m / 13.2m)
NOPAT = 31.0m (EBIT 56.4m * (1 - 45.07%))
Current Ratio = 2.07 (Total Current Assets 222.4m / Total Current Liabilities 107.2m)
Debt / Equity = 0.74 (Debt 206.3m / totalStockholderEquity, last quarter 279.8m)
Debt / EBITDA = 2.41 (Net Debt 183.5m / EBITDA 76.2m)
Debt / FCF = 8.00 (Net Debt 183.5m / FCF TTM 22.9m)
Total Stockholder Equity = 266.4m (last 4 quarters mean from totalStockholderEquity)
RoA = 5.36% (Net Income 31.8m / Total Assets 597.0m)
RoE = 11.94% (Net Income TTM 31.8m / Total Stockholder Equity 266.4m)
RoCE = 14.81% (EBIT 56.4m / Capital Employed (Equity 266.4m + L.T.Debt 114.1m))
RoIC = 8.08% (NOPAT 31.0m / Invested Capital 383.0m)
WACC = 9.61% (E(880.7m)/V(1.09b) * Re(11.74%) + D(206.3m)/V(1.09b) * Rd(0.92%) * (1-Tc(0.45)))
Discount Rate = 11.74% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -1.12%
[DCF Debug] Terminal Value 76.22% ; FCFF base≈31.1m ; Y1≈38.4m ; Y5≈65.4m
Fair Price DCF = 13.92 (EV 831.6m - Net Debt 183.5m = Equity 648.1m / Shares 46.6m; r=9.61% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 53.14 | EPS CAGR: 29.35% | SUE: 1.33 | # QB: 2
Revenue Correlation: 74.94 | Revenue CAGR: 4.97% | SUE: 2.79 | # QB: 2
EPS next Quarter (2026-03-31): EPS=0.15 | Chg30d=+0.000 | Revisions Net=-1 | Analysts=2
EPS current Year (2026-12-31): EPS=0.75 | Chg30d=+0.000 | Revisions Net=-2 | Growth EPS=-0.4% | Growth Revenue=-2.2%